Alpha Cognition Inc. (NASDAQ: ACOG) reported second-quarter 2026 results that underscore the strengthening launch of its Alzheimer's treatment ZUNVEYL, with net product revenue surging 71% quarter-over-quarter to $6.0 million. The company, which is developing therapies for neurodegenerative diseases, saw bottles dispensed increase 37% to 8,294, with June alone reaching 2,997 bottles, the strongest month since launch. This growth occurred without material stocking benefit and with downstream pharmacy benefit manager (PBM) implementation unchanged at approximately 16%, suggesting that the quarter's performance was driven primarily by genuine demand and improved commercial execution.
The importance of these results lies in the quality of the quarter relative to the access backdrop. While broader formulary coverage remains limited, prescriptions, repeat use, and facility adoption advanced. The number of quarterly prescribers reached 1,347, with 1,024 repeat prescribers, 1,908 cumulative writers, and 1,095 long-term care (LTC) facilities generating prescriptions during the quarter. This broadening adoption, coupled with deepening repeat utilization, provides a solid foundation for continued growth even before potential payer expansion.
Management indicated that growth continued into the third quarter, and the company is balancing commercial investment with a growing evidence base. Alpha Cognition lowered its full-year 2026 R&D and SG&A guidance to $50 million to $54 million while maintaining its 2027 operating profitability target. Several key milestones are anticipated, including CONVERGE data expected in the third quarter of 2026, the ongoing RESOLVE study, and the sublingual program gated by comparative pharmacokinetic results. These developments could provide additional catalysts as the company works toward greater operating leverage.
The ZUNVEYL launch setup is increasingly characterized by breadth, depth, and payer upside. White space remains across healthcare providers and facilities, utilization is deepening among existing prescribers, and broader PBM implementation remains an incremental growth driver. With payer access still at roughly 16%, there is significant potential for revenue acceleration if formulary coverage expands. The company's ability to achieve strong sales despite limited access speaks to the product's clinical value and the effectiveness of its commercial strategy.
As Alpha Cognition continues to execute on its launch, the combination of robust demand, a clear path to profitability, and upcoming data readouts positions the company for sustained progress. Investors and industry observers will be watching closely for updates on payer negotiations and clinical trial results, which could further validate ZUNVEYL's market potential and the company's long-term growth prospects.
